| For: | Makri E, Cholongitas E, Tziomalos K. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22(41): 9039-9043 [PMID: 27895393 DOI: 10.3748/wjg.v22.i41.9039] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i41/9039.htm |
| Number | Citing Articles |
| 1 |
Xiao Yang, Frank J. Gonzalez, Min Huang, Huichang Bi. Nuclear receptors and non-alcoholic fatty liver disease: An update. Liver Research 2020; 4(2) doi: 10.1016/j.livres.2020.03.001
|
| 2 |
Simona Cernea, Avivit Cahn, Itamar Raz. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Review of Clinical Pharmacology 2017; 10(5) doi: 10.1080/17512433.2017.1300059
|
| 3 |
Marc S. Rendell. Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetes. Expert Opinion on Pharmacotherapy 2021; 22(16) doi: 10.1080/14656566.2021.1958779
|
| 4 |
Vik Meadows, Lindsey Kennedy, Debjyoti Kundu, Gianfranco Alpini, Heather Francis. Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases. Frontiers in Medicine 2020; 7 doi: 10.3389/fmed.2020.00015
|
| 5 |
Alaa M. Mostafa, Ziyan Pan, Ming-Lung Yu, Necati Örmeci, Yasser Fouad, Mohammed Eslam. MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk. Hepatic Medicine: Evidence and Research 2025; doi: 10.2147/HMER.S506402
|
| 6 |
Maria Vasco, Rossella Paolillo, Concetta Schiano, Linda Sommese, Oreste Cuomo, Claudio Napoli. Compromised nutritional status in patients with end-stage liver disease: Role of gut microbiota. Hepatobiliary & Pancreatic Diseases International 2018; 17(4) doi: 10.1016/j.hbpd.2018.06.004
|
| 7 |
Maria Ryaboshapkina, Mårten Hammar. Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-10930-w
|
| 8 |
Hongkui Wu, Gang Liu, Yaoli He, Jing Da, Bingqing Xie. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice. European Journal of Pharmacology 2019; 858 doi: 10.1016/j.ejphar.2019.05.022
|
| 9 |
Joseph M Pappachan, Shithu Babu, Babu Krishnan, Nishal C Ravindran. Non-alcoholic Fatty Liver Disease: A Clinical Update. Journal of Clinical and Translational Hepatology 2017; (XX) doi: 10.14218/JCTH.2017.00013
|
| 10 |
Mariana Boulos, Rabia S. Mousa, Nizar Jeries, Elias Simaan, Klode Alam, Bulus Bulus, Nimer Assy. Hidden in the Fat: Unpacking the Metabolic Tango Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome. International Journal of Molecular Sciences 2025; 26(7) doi: 10.3390/ijms26073448
|
| 11 |
Lucienne Juillerat-Jeanneret, John-David Aubert, Josip Mikulic, Dela Golshayan. Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction. Journal of Medicinal Chemistry 2018; 61(22) doi: 10.1021/acs.jmedchem.8b00294
|
| 12 |
Michal Herman-Edelstein, Talia Weinstein, Moshe Levi. Bile acid receptors and the kidney. Current Opinion in Nephrology and Hypertension 2018; 27(1) doi: 10.1097/MNH.0000000000000374
|
| 13 |
Ahmed Lotfy, Shimaa El-Metwaly, Reham Soliman, Ayman A. Hassan, Gamal Shiha. Umbilical Cord Mesenchymal Stem/Stromal Cells and Low-Dose Obeticholic Acid as a Possible Combined Treatment for Liver Fibrosis. Stem Cell Reviews and Reports 2022; 18(5) doi: 10.1007/s12015-022-10346-8
|
| 14 |
Savinda Liyanagedera, Robert Patrick Williams, Silvio Veraldi, Valerio Nobili, Jake P. Mann. The pharmacological management of NAFLD in children and adolescents. Expert Review of Clinical Pharmacology 2017; 10(11) doi: 10.1080/17512433.2017.1365599
|
| 15 |
Giuseppina Palladini, Marta Cagna, Laura Giuseppina Di Pasqua, Luciano Adorini, Anna Cleta Croce, Stefano Perlini, Andrea Ferrigno, Clarissa Berardo, Mariapia Vairetti. Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in Rats. Pharmaceuticals 2022; 15(5) doi: 10.3390/ph15050524
|
| 16 |
Nasser Alorfi, Ahmed Ashour. The Impact of Intermittent Fasting on Non-Alcoholic Fatty Liver Disease in Older Adults: A Review of Clinicaltrials.gov Registry. Diabetes, Metabolic Syndrome and Obesity 2023; doi: 10.2147/DMSO.S430740
|
| 17 |
Shentian Zhuang, Qiang Li, Lirong Cai, Chu Wang, Xiaoguang Lei. Chemoproteomic Profiling of Bile Acid Interacting Proteins. ACS Central Science 2017; 3(5) doi: 10.1021/acscentsci.7b00134
|
| 18 |
Vik Meadows, Lindsey Kennedy, Burcin Ekser, Konstantina Kyritsi, Debjyoti Kundu, Tianhao Zhou, Lixian Chen, Linh Pham, Nan Wu, Jennifer Demieville, Laura Hargrove, Shannon Glaser, Gianfranco Alpini, Heather Francis. Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling. Hepatology 2021; 74(5) doi: 10.1002/hep.32028
|
| 19 |
Michelle Ma, Katie Falloon, Po-Hung Chen, Behnam Saberi, Aliaksei Pustavoitau, Elif Ozdogan, Zhiping Li, Benjamin Philosophe, Andrew M. Cameron, Ahmet Gurakar. The Role of Liver Transplantation in Alcoholic Hepatitis. Journal of Intensive Care Medicine 2019; 34(4) doi: 10.1177/0885066618780339
|
| 20 |
CS Gautam, Jatin Sharma, Mandeep Singla, Ilmjot Kaur Tiwana, Harmanjit Singh. Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls. touchREVIEWS in Endocrinology 2021; 17(1) doi: 10.17925/EE.2021.17.1.33
|
| 21 |
Bandar D. Alrehaili. Unravelling the therapeutic landscape of bile acid-based therapies in gastrointestinal disorders. Saudi Journal of Gastroenterology 2024; 30(5) doi: 10.4103/sjg.sjg_53_24
|
| 22 |
Evangelia S. Makri, Eleftheria Makri, Stergios A. Polyzos. Combination Therapies for Nonalcoholic Fatty Liver Disease. Journal of Personalized Medicine 2022; 12(7) doi: 10.3390/jpm12071166
|
| 23 |
Vasilios G. Athyros, Theodore K. Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S. Ganotakis, John Goudevenos, Moses S. Elisaf, Georgios Germanidis, Olga Giouleme, Asterios Karagiannis, Charalambos Karvounis, Niki Katsiki, Vasilios Kotsis, Jannis Kountouras, Evangelos Liberopoulos, Christos Pitsavos, Stergios Polyzos, Loukianos S. Rallidis, Dimitrios Richter, Apostolos G. Tsapas, Alexandros D. Tselepis, Konstantinos Tsioufis, Konstantinos Tziomalos, Themistoklis Tzotzas, Themistoklis G. Vasiliadis, Charalambos Vlachopoulos, Dimitri P. Mikhailidis, Christos Mantzoros. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71 doi: 10.1016/j.metabol.2017.02.014
|
| 24 |
Eunsol Choi, Eungyeong Jang, Jang-Hoon Lee. Pharmacological Activities of Alisma orientale against Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: Literature Review. Evidence-Based Complementary and Alternative Medicine 2019; 2019 doi: 10.1155/2019/2943162
|
| 25 |
Sukhpreet Singh, Natalia A Osna, Kusum K Kharbanda. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World Journal of Gastroenterology 2017; 23(36): 6549-6570 doi: 10.3748/wjg.v23.i36.6549
|
| 26 |
Monjur Ahmed. Non-Alcoholic Fatty Liver Disease - Molecular Bases, Prevention and Treatment. 2018; doi: 10.5772/intechopen.72000
|
| 27 |
CS Gautam, Jatin Sharma, Mandeep Singla, Ilmjot Kaur Tiwana, Harmanjit Singh. Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls. European Endocrinology 2021; 1(1) doi: 10.17925/EE.2021.1.1.33
|
| 28 |
Mengjie Kong, Yan Peng, Liyan Qiu. Oligochitosan-based nanovesicles for nonalcoholic fatty liver disease treatment via the FXR/miR-34a/SIRT1 regulatory loop. Acta Biomaterialia 2023; 164 doi: 10.1016/j.actbio.2023.04.002
|
| 29 |
L. B. Lazebnik, S. V. Turkina, E. V. Golovanova. Targeted use of hepatoprotectors for the treatment of various stages of non-alcoholic fatty liver disease (fatty degeneration of the liver according to ICD 10) and associated comorbid conditions; tables for medical use. Experimental and Clinical Gastroenterology 2024; (10) doi: 10.31146/1682-8658-ecg-230-10-11-35
|
| 30 |
S Singh, KK Kharbanda. Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A Review. Archives of Hepatitis Research 2017; 3(1) doi: 10.17352/ahr.000014
|
| 31 |
Asmaa A. Aboushouk, Hebatallah M. Saad, Aya H. Rohiem, Dina R.S. Gad El-Karim. New Insights on the potential therapeutic effects of glibenclamide and Obeticholic acid against Alloxan-Induced diabetes mellitus in rat model. International Immunopharmacology 2024; 143 doi: 10.1016/j.intimp.2024.113469
|
| 32 |
Eloy D. Hernandez, Lianxing Zheng, Young Kim, Bin Fang, Bo Liu, Reginald A. Valdez, William F. Dietrich, Paul V. Rucker, Donatella Chianelli, James Schmeits, Dingjiu Bao, Jocelyn Zoll, Claire Dubois, Glenn C. Federe, Lihao Chen, Sean B. Joseph, Lloyd B. Klickstein, John Walker, Valentina Molteni, Peter McNamara, Shelly Meeusen, David C. Tully, Michael K. Badman, Jie Xu, Bryan Laffitte. Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents. Hepatology Communications 2019; 3(8) doi: 10.1002/hep4.1368
|
| 33 |
Lin Zhuang, Wenbin Ding, Qi Zhang, Wei Ding, Xuezhong Xu, Xiaolong Yu, Dong Xi. TGR5 Attenuated Liver Ischemia-Reperfusion Injury by Activating the Keap1-Nrf2 Signaling Pathway in Mice. Inflammation 2021; 44(3) doi: 10.1007/s10753-020-01382-y
|
| 34 |
Michael J. Nash, Evgenia Dobrinskikh, Saif I. Al‐Juboori, Rachel C. Janssen, Jolyn Fernandes, Amy Argabright, Angelo D'Alessandro, Melissa A. Kirigiti, Paul Kievit, Kjersti M. Aagaard, Carrie E. McCurdy, Maureen Gannon, Kenneth L. Jones, Tiangang Li, Jacob E. Friedman, Stephanie R. Wesolowski. Maternal Western Diet Programmes Bile Acid Dysregulation and Hepatic Fibrosis in Fetal and Juvenile Macaques. Liver International 2025; 45(2) doi: 10.1111/liv.16236
|
| 35 |
Maryam Mahjoubin-Tehran, Antonio De Vincentis, Dimitri P. Mikhailidis, Stephen L. Atkin, Christos S. Mantzoros, Tannaz Jamialahmadi, Amirhossein Sahebkar. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Molecular Metabolism 2021; 50 doi: 10.1016/j.molmet.2020.101049
|